You are hereJune 11, 2019
Incubation with Extracellular Vesicles Boosts Cells’ Grafting Ability
DURHAM, N.C. JUNE 11, 2019 - A study released today in STEM CELLS demonstrates how extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying their gene expression and increasing their viability and cloning ability. In a test on mice, MSC-EVs also increased the cells’ ability to lodge into bone marrow. This research performed by Prof. Sanchez-Guijo’s Lab at the IBSAL-University of Salamanca (Spain) could potentially overcome serious complications due to graft failure or poor engraftment from allogeneic stem cell transplantation.
In its search for how to overcome poor stem cell engraftment, the medical world has focused its attention on MSCs, which have been shown to increase the engraftment ability and the hematopoietic function in mice. Some of the beneficial effects of MSC can be exerted through the release of EV — small, membrane-derived particles that selectively carry RNA, lipids and proteins that can be incorporated into recipient cells and modify their function.
“Recent studies have demonstrated that EV released by MSC could have similar effects to those of MSC,” said the study’s corresponding author, Sandra Muntión, Ph.D., of the Hospital Universitario de Salamanca in Spain. “In the current work, we wanted to evaluate the changes induced in CD34+ cells after the incorporation of MSC-derived EV. Moreover, we have assessed if this incorporation has functional implications, evaluating their clonogenic ability in vitro and the in vivo engraftment in a mouse model.”
After incubating the CD34+ cells in the MSC-EV and comparing them to non-incubated cells, “Our in vitro results showed that MSC-EV incorporation induced a downregulation of pro-apoptotic genes, an overexpression of genes involved in colony formation and an activation of the JAK-STAT pathway in CD34+ cells,” reported Silvia Preciado, first author of the manuscript. “A significant decrease in apoptosis and an increased CD44 expression were confirmed, too. In addition, these cells displayed a higher clonogenic potential.”
The in vivo studies produced similar results. The tests were conducted on non-obese diabetic, severe combined immunodeficient mice. One group was treated with non-incubated CD34+ cells, and the other with CD34+ cells that were incubated with MSC-EV for 24 hours. The cells were then injected into the femurs of the mice. Four weeks later, the researchers found that the bone marrow lodging ability of the human CD34+ cells with MSC-EV was significantly higher than the control group of CD34+ cells.
Dr. Jan Nolta, Editor-in-Chief of STEM CELLS, said, “This is an important demonstration of a pathway by which bone marrow stromal cells can positively affect the fate of human hematopoietic stem cells. In addition to the long-known release of growth factors from the stromal cells, researchers from Prof. Sanchez-Guijo’s team have now shown that stromal-derived exosomes can also stimulate the hematopoietic stem cells. This new discovery could potentially lead to improved transplantation outcomes.”
“In summary, we found that the incorporation of MSC-EV induces genomic and functional changes in CD34+ cells, increasing their clonogenic capacity and their bone marrow lodging ability,” Dr. Muntión concluded.
The full article, “The incorporation of extracellular vesicles from MSC into CD34+ cells increase their clonogenic capacity and bone marrow lodging ability,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3032.
About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.